DARÉ BIOSCIENCE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.3059 USD | +5.77% |
|
+9.25% | -1.00% |
Presentation Operator MessageOperator (Operator)Welcome to the conference hosted by Dare Biosc...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.3059
USD
Average target price
4.667
USD
Spread / Average Target
+1,425.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.00% | 30.77M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- DARE Stock
- News Daré Bioscience, Inc.
- Transcript : Daré Bioscience, Inc., Q2 2023 Earnings Call, Aug 10, 2023
